Akebia delays Form 10-Q filing due to accounting errors; reaffirms 2023 revenue guidance

Akebia Therapeutics, Inc.

Identified accounting errors in recording Auryxia return reserves, delaying Q2 2023 Form 10-Q filing.
Reaffirms 2023 Auryxia net product revenue guidance of $175-$180 million.
Cash as of June 30, 2023 plus Auryxia revenues expected to fund operations through at least next twelve months.
Expects to resubmit NDA for vadadustat for anemia due to CKD in dialysis patients by end of Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.